Search results
Timothy "Tim" A. Springer (born February 23, 1948) is an immunologist and the Latham Family Professor at Harvard Medical School. [5] He is also a professor at the Department of Biological Chemistry and Molecular Pharmacology and of the Division of Medical Sciences , [ 5 ] and a Senior Investigator at the Research Program in Cellular and ...
Since 1989 Springer has been Latham Family Professor. He currently is Professor of Biological Chemistry and Molecular Pharmacology and of Medicine at HMS and in the Program of Cellular and Molecular Medicine, and in the Division of Hematology, Department of Medicine at Children’s Hospital.
Springer is an investor in Selecta Bioscience since its B round and a founding investor in Moderna Therapeutics. He is a Resident Professor at Pfizer. He is founder and investor in Scholar Rock and in Morphic Rock Therapeutics, and board member and lead angel of Ab Initio Biotherapeutics.
smartphone 617-713-8200. email springer@crystal.harvard.edu. We work on receptor-ligand interactions and signal transmission across membranes. We use a wide range of structural, cell biological, and single molecule techniques to answer important questions relevant to immunology, hemostasis, mammalian biology, and human disease.
Please find all of Timothy Springer's authored publications at his PubMed bibliography.
Timothy A. Springer is a senior investigator and professor at Boston Children's Hospital and Harvard Medical School. He is a renowned expert on adhesion receptors, integrins, and protein therapeutics, and a recipient of the 2022 Lasker Basic Medical Research Award.
Timothy SPRINGER | Cited by 109,225 | of Harvard University, MA (Harvard) | Read 573 publications | Contact Timothy SPRINGER
